Skip to main content

PDE5 Inhibitors

PDE5 inhibitors are among the most versatile drug classes in contemporary urology. They carry two FDA-approved urologic indications — erectile dysfunction (all four agents: sildenafil, tadalafil, vardenafil, avanafil) and LUTS/BPH (tadalafil 5 mg daily only) — plus a broad off-label footprint covering post-prostatectomy penile rehabilitation, Peyronie's disease, recurrent ischemic priapism, premature ejaculation, medical expulsive therapy for ureteral stones, and investigational renal and female-sexual-dysfunction uses.[1][2][3]

For related classes, see Intracavernosal injection agents, Intraurethral alprostadil, Peyronie's disease agents, Priapism management, and α-blockers / voiding-outlet.

Mechanism​

PDE5 inhibitors block phosphodiesterase type 5 and prevent the hydrolysis of cyclic GMP generated by the NO–sGC cascade in smooth muscle. Sustained cGMP drops intracellular calcium, keeps smooth muscle relaxed, and — in the corpus cavernosum — permits erection when sexual stimulation is present.[1][2]

PDE5 is also expressed in the prostate (especially the transition zone), detrusor, ureteral smooth muscle, pulmonary vasculature, and systemic resistance vessels. This expanded anatomic footprint is the mechanistic basis for every off-label urologic application that follows.[2][3]

Agents​

AgentOn-demandDailyOnsetDurationPractical differentiators
Sildenafil25 / 50 / 100 mgNot approved daily30–60 min~4 hHighest efficacy in network MA; food and alcohol delay absorption[4]
Tadalafil10 / 20 mg2.5 / 5 mg30–60 minUp to 36 hOnly PDE5i approved for daily use and the only agent FDA-approved for LUTS/BPH[5][6]
Vardenafil10 / 20 mgNot approved daily30–60 min4–5 hAvoid with class IA or III antiarrhythmics and congenital long-QT; ODT formulation available
Avanafil50 / 100 / 200 mgNot approved daily15–30 min~6 hFastest onset; lower flushing and visual AEs in head-to-head data

Network meta-analyses of trade-off between efficacy and adverse events place sildenafil highest on absolute efficacy, with tadalafil offering the best tolerability and duration, and avanafil a favorable AE profile at reduced efficacy.[4][7]

Erectile dysfunction — FDA-approved first-line​

Per AUA ED guideline 2018:[8]

  • PDE5 inhibitors are first-line pharmacologic therapy for ED, with pooled response rates ≥65% across agents
  • Titrate dose to optimal efficacy
  • Give clear instructions (timing relative to meals, need for sexual stimulation, appropriate interval before intercourse)
  • Try each agent at least 4–6 times before judging failure
  • If one agent fails, switch to a different PDE5 inhibitor at maximal dose for ≥6 additional attempts
  • Correct hypogonadism — testosterone supplementation in hypogonadal men improves PDE5i responsiveness[9]

Up to 35% of patients fail to respond; the dominant predictors are diabetes mellitus, severe vascular disease, and neurologic injury.[1] See Testosterone replacement and Intracavernosal injection agents for escalation.

LUTS / BPH — tadalafil 5 mg daily​

Tadalafil 5 mg daily is the only PDE5i FDA-approved for LUTS/BPH. Pooled RCT data show IPSS improvement of ~5.6 points vs placebo, with response as early as 4 weeks.[2][3]

Mechanisms relevant to the lower urinary tract:[2]

  • Lower-urinary-tract oxygenation
  • Prostatic and bladder-neck smooth-muscle relaxation
  • Negative regulation of prostatic stromal proliferation
  • Reduced bladder afferent activity
  • Downregulation of prostate inflammation

Key advantages vs α-blockers:

  • Preserves or improves sexual function — a major advantage in men with concurrent LUTS and ED
  • Wei 2025 JAMA: tadalafil may be used instead of or in combination with α-blocker therapy, even in men without ED; AE-driven discontinuation is uncommon[10]

Combination therapy — Zhang 2019 meta-analysis (11 RCTs, n = 855) — PDE5i + α-blocker vs α-blocker alone: IPSS (MD −1.66), Qmax (+0.94 mL/s), IIEF (+4.73).[11] The AUA BPH amendment 2023 notes that the specific tadalafil 5 mg + α-blocker combination for BPH has not been adequately studied for combined efficacy; the tadalafil label recommends discontinuing the α-blocker at least one day before starting tadalafil for BPH to avoid orthostatic hypotension.[12][13]

Combination with 5α-reductase inhibitors — AUA conditional recommendation (Grade C) permits tadalafil 5 mg with finasteride, though long-term data are limited.[12] See 5α-reductase inhibitors and α-blockers.

Penile rehabilitation after radical prostatectomy​

The first-line rehabilitation strategy per the ACS Prostate Cancer Survivorship Guideline and consensus expert documents.[14][15] Rationale: cavernosal nerve neuropraxia drives pro-apoptotic and pro-fibrotic changes in corporal smooth muscle; scheduled PDE5i maintains tissue oxygenation and counters structural deterioration during the recovery window.[16][17]

Evidence:

  • Sari Motlagh 2021 network meta-analysis (22 RCTs, n = 2,711) — sildenafil 100 mg regularly (daily/nightly) was the best rehabilitation strategy (OR 4.00; 95% CrI 1.40–13.4; moderate certainty). On-demand dosing was not superior to placebo for rehabilitation.[18]
  • REACTT (Montorsi 2014, n = 423) — tadalafil 5 mg daily was most effective for drug-assisted erectile function and reduced penile-length loss (LS mean diff 4.1 mm vs placebo; p = 0.032); unassisted erectile function was not improved after 6-week drug-free washout[19]
  • Jo 2018 RCT — immediate sildenafil after catheter removal produced 41.4% full recovery at 12 months vs 17.7% delayed (HR 2.94; p = 0.034)[20]
  • Combined PDE5i + VED ± ICI protocols achieve full recovery in up to 80% at 2 years in academic rehabilitation programs[21][22]
  • The ACS survivorship guideline recommends revisiting PDE5i even after initial failure — recovery can extend 2–4 years post-op[15]

See Intracavernosal injection agents and Intraurethral alprostadil for combination escalation.

Recurrent ischemic (stuttering) priapism​

Counterintuitively, regimented daily PDE5 inhibitor therapy is used to prevent recurrent ischemic priapism — the mechanistic argument is that chronic PDE5i administration reconditions downregulated PDE5 regulatory function in the penis, restoring the normal feedback balance of corporal tone, particularly in SCD patients with NO-resistant priapism.[23][24]

  • AUA/SMSNA Priapism guideline 2022 — PDE5 inhibitors (tadalafil or sildenafil) are listed among preventive strategies for recurrent ischemic priapism; optimal regimens are unknown (Conditional Recommendation; Grade C)[25]
  • Hou & Burnett 2021 retrospective — regimented PDE5i therapy decreased ED visits for recurrent ischemic priapism by ~4.4-fold (p < 0.05)[26]
  • Burnett 2006 early case series (n = 7; 4 SCD, 3 idiopathic) — 6 of 7 patients had alleviation or resolution with preserved erectile function[23]

Practical regimen: tadalafil 5 mg daily, administered in the morning (not at bedtime — sleep-related erections are the dominant trigger in recurrent ischemic priapism, so PDE5 reconditioning is desired during waking hours).

See Priapism management.

Peyronie's disease​

PDE5 inhibitors exert antifibrotic effects — inhibiting myofibroblast transformation and reducing ECM production in the tunica albuginea — alongside their erectogenic role. The primary use is managing concomitant ED during the acute phase of PD.[27][28]

  • Spirito 2024 retrospective (n = 191) — daily tadalafil 5 mg reduced penile-curvature progression (25.9% vs 39.7%; p = 0.042) and improved IIEF-5 and PD symptoms at 12 weeks[29]
  • Ilg 2019 preclinical — synergistic antifibrotic effect between vardenafil and the SERM tamoxifen in both in-vitro and in-vivo PD models[27]
  • Chung 2011 — daily low-dose tadalafil produced 69% ultrasound resolution of isolated septal scars vs 10% controls[30]
  • Alzubaidi 2025 — combined CCH + VED + daily tadalafil 5 mg achieved 21.4% mean curvature improvement with significant IIEF gain[31]

Important framing: the Rosenberg 2023 Cochrane review of non-surgical PD therapies excluded PDE5i from the primary analysis because they are used to treat concomitant ED rather than the curvature itself — the disease-modifying case remains exploratory.[32] See Peyronie's disease agents.

Premature ejaculation (off-label)​

Proposed mechanisms include central NO/cGMP effects, peripheral vas deferens / seminal vesicle relaxation, peripheral analgesia, and prolonged erection duration.[33]

  • Sun 2017 meta-analysis (23 RCTs, n = 6,145) — PDE5i were significantly more effective than placebo or SSRIs for PE (p < 0.05)[34]
  • Jin 2018 network meta — sildenafil superior to sertraline on IELT (MD 1.63 min; 95% CrI 0.10–2.79)[35]
  • Currently only dapoxetine and lidocaine/prilocaine spray (Fortacin) are regulatory-approved for PE; PDE5i are off-label and are recommended either as monotherapy or combined with dapoxetine / topical anesthetics per expert-review pharmacotherapy overviews[36]

See SNRIs and Local anesthetics for the PE therapeutic context.

Medical expulsive therapy for ureteral stones (off-label)​

PDE5i relax ureteral smooth muscle via the NO/cGMP pathway; tadalafil is the most studied agent in this setting.

  • Sun 2024 pooled analysis (14 studies) — tadalafil enhanced stone expulsion (OR 0.68; p = 0.04), reduced expulsion time (MD −1.22 days; p = 0.03), and cut analgesic use vs tamsulosin[37]
  • Sharma 2021 network MA (50 RCTs; n = 12,382) — tadalafil + silodosin ranked best for both expulsion rate and time; silodosin was the best single drug[38]
  • Liu 2020 network MA (78 RCTs; n = 14,922) — silodosin + tadalafil best probability for reduced expulsion time; tamsulosin + tadalafil best for pain reduction[39]

Not yet a first-line MET recommendation in AUA/EAU guidelines but a legitimate adjunct to α-blockers in selected distal-stone patients, and a useful option when ED is also being addressed.

Female sexual dysfunction and renal protection — investigational​

Female sexual dysfunction — not FDA-approved. ACOG 2019 states sildenafil should not be used for female interest/arousal disorders outside of clinical trials.[40] Small studies suggest possible benefit in SCI-associated, antidepressant-associated, and T1DM-associated arousal disorders.[41] Gao 2016 meta-analysis (14 RCTs) found improvement on some sexual-function endpoints, but results were inconsistent and AEs (headache, flushing) were significantly higher.[42]

Renal protection — preclinical and early clinical. Animal models of AKI show reno-protective effects via regional hemodynamics, anti-apoptosis, and antioxidant pathways.[43] Sildenafil pretreatment improved renal vascular flow in warm-ischemic kidneys in a transplant model.[44] In actual kidney transplant recipients, PDE5i are effective and well tolerated for ED but tacrolimus prolongs PDE5i half-life and precludes daily dosing due to hypotension risk.[45][46]

Contraindications and safety​

Absolute contraindications​

  • Concomitant nitrate use — the most critical interaction. Sildenafil / vardenafil require ≥24 h washout before nitrates; tadalafil ≥48 h. A Swedish registry (n = 55,777) found combined use was associated with higher all-cause mortality (HR 1.39), CV mortality (HR 1.34), and MI (HR 1.72).[47][48]
  • History of non-arteritic anterior ischemic optic neuropathy (NAION)
  • Retinitis pigmentosa

Use with caution​

  • α-blockers — risk of symptomatic hypotension; initiate at lowest dose with stepwise titration[13]
  • Uncontrolled hypertension, unstable angina, recent MI or stroke
  • Autonomic dysfunction (multiple system atrophy, high SCI) — higher hypotension risk[49]
  • Vardenafil specifically: avoid with class IA (quinidine, procainamide) or class III (sotalol, amiodarone) antiarrhythmics and in congenital long-QT syndrome[1]
  • Concurrent strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) — reduce dose and increase interval

Common adverse effects​

Generally mild and dose-dependent: headache (most common), flushing, dyspepsia, nasal congestion, visual disturbances (especially sildenafil — blue-tinted vision from PDE6 cross-inhibition), myalgia/back pain (especially tadalafil), and — rarely — priapism or sudden sensorineural hearing loss.[1]

Evidence Summary​

ApplicationAgent(s)FDA statusEvidence levelKey source
Erectile dysfunctionSildenafil / tadalafil / vardenafil / avanafilApprovedLevel 1AUA 2018[8]; Chen 2015 network MA[4]
LUTS/BPHTadalafil 5 mg dailyApprovedLevel 1Pattanaik 2018 Cochrane[7]; AUA 2023[12]
Post-RP rehabilitationSildenafil / tadalafil dailyOff-labelLevel 1Sari Motlagh 2021 network MA[18]; REACTT[19]
Recurrent ischemic priapismTadalafil / sildenafil regimentedOff-labelLevel 3AUA/SMSNA 2022[25]; Hou 2021[26]
Peyronie's diseaseTadalafil 5 mg dailyOff-labelLevel 2–3Spirito 2024[29]; Ilg 2019[27]
Premature ejaculationSildenafil / tadalafilOff-labelLevel 1Sun 2017 MA[34]; Jin 2018[35]
MET for ureteral stonesTadalafil (± α-blocker)Off-labelLevel 1Sun 2024[37]; Sharma 2021[38]
Female sexual dysfunctionSildenafilNot approvedLevel 2 (conflicting)ACOG 2019[40]; Gao 2016[42]
Renal protectionSildenafilInvestigationalPreclinical / smallGeorgiadis 2020 SR[43]

Clinical Positioning​

  • PDE5i are first-line for ED — try at least one agent at maximum dose ≥6 times before declaring failure; if unsuccessful, switch to a second PDE5i before abandoning the class.[8]
  • Correct hypogonadism before escalating — low testosterone impairs PDE5i response; replacement restores it in many non-responders.[9]
  • Tadalafil 5 mg daily is the PDE5i for LUTS — improves IPSS by ~5.6 points and preserves sexual function; uniquely useful in men with coexisting LUTS and ED.[3][6][10]
  • Combination with α-blocker for BPH is pharmacologically defensible but requires the 1-day α-blocker washout before starting tadalafil; not a formally guideline-endorsed efficacy combination.[12][13]
  • Post-RP rehabilitation requires scheduled, not on-demand, dosing — sildenafil 100 mg nightly and tadalafil 5 mg daily are the best-evidenced strategies; on-demand is no better than placebo for this indication.[18]
  • Start rehabilitation early. Immediate post-catheter-removal initiation (Jo 2018) more than doubled 12-month full-recovery odds.[20]
  • Regimented daily PDE5i is the pharmacologic prevention for recurrent ischemic priapism — morning dosing, tadalafil 5 mg is the practical default.[25][26]
  • In Peyronie's, PDE5i primarily treat concomitant ED; the antifibrotic signal is real preclinically but not established as a disease-modifying first-line.[29][32]
  • For PE, PDE5i are a legitimate off-label adjunct — combine with dapoxetine or topical anesthetic rather than as sole therapy when other first-line options are available.[34][36]
  • The nitrate interaction is absolute — 48-h washout for tadalafil, 24-h for sildenafil / vardenafil. The Trolle Lagerros 2024 registry data confirm mortality signal with combined use; this warning is load-bearing.[47][48]
  • α-blocker pre-existing users — initiate PDE5i at lowest dose with stepwise titration; counsel about orthostatic hypotension and the 1-day washout for tadalafil BPH indication.[13]
  • Kidney transplant recipients on tacrolimus — do not use daily tadalafil; on-demand dosing only, with expected hypotension risk from PK interaction.[46]

See Also​

References​

1. Shamloul R, Ghanem H. "Erectile dysfunction." Lancet. 2013;381(9861):153–165. doi:10.1016/S0140-6736(12)60520-0

2. Gacci M, Andersson KE, Chapple C, et al. "Latest evidence on the use of phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia." Eur Urol. 2016;70(1):124–133. doi:10.1016/j.eururo.2015.12.048

3. Sarma AV, Wei JT. "Benign prostatic hyperplasia and lower urinary tract symptoms." N Engl J Med. 2012;367(3):248–257. doi:10.1056/NEJMcp1106637

4. Chen L, Staubli SE, Schneider MP, et al. "Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis." Eur Urol. 2015;68(4):674–680. doi:10.1016/j.eururo.2015.03.031

5. US Food and Drug Administration. Tadalafil — prescribing information. Updated 2024-09-05.

6. Mónica FZ, De Nucci G. "Tadalafil for the treatment of benign prostatic hyperplasia." Expert Opin Pharmacother. 2019;20(8):929–937. doi:10.1080/14656566.2019.1589452

7. Pattanaik S, Mavuduru RS, Panda A, et al. "Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia." Cochrane Database Syst Rev. 2018;11:CD010060. doi:10.1002/14651858.CD010060.pub2

8. Burnett AL, Nehra A, Breau RH, et al. "Erectile dysfunction: AUA guideline." J Urol. 2018;200(3):633–641. doi:10.1016/j.juro.2018.05.004

9. Pyrgidis N, Mykoniatis I, Haidich AB, et al. "The effect of phosphodiesterase-type 5 inhibitors on erectile function: an overview of systematic reviews." Front Pharmacol. 2021;12:735708. doi:10.3389/fphar.2021.735708

10. Wei JT, Dauw CA, Brodsky CN. "Lower urinary tract symptoms in men." JAMA. 2025;334(9):809–821. doi:10.1001/jama.2025.7045

11. Zhang J, Li X, Yang B, et al. "Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis." World J Urol. 2019;37(1):143–153. doi:10.1007/s00345-018-2370-z

12. Sandhu JS, Bixler BR, Dahm P, et al. "Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline amendment 2023." J Urol. 2024;211(1):11–19. doi:10.1097/JU.0000000000003698

13. US Food and Drug Administration. Tadalafil — BPH label and α-blocker interaction. Updated 2024.

14. Lombardo R, Tema G, De Nunzio C. "Phosphodiesterase 5 inhibitors and erectile dysfunction recovery after pelvic surgery: future perspectives for new drugs and new formulations." Curr Drug Targets. 2021;22(1):31–37. doi:10.2174/1389450121666200925145347

15. Skolarus TA, Wolf AM, Erb NL, et al. "American Cancer Society prostate cancer survivorship care guidelines." CA Cancer J Clin. 2014;64(4):225–249. doi:10.3322/caac.21234

16. Hatzimouratidis K, Burnett AL, Hatzichristou D, et al. "Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application." Eur Urol. 2009;55(2):334–347. doi:10.1016/j.eururo.2008.10.028

17. Philippou YA, Jung JH, Steggall MJ, et al. "Penile rehabilitation for postprostatectomy erectile dysfunction." Cochrane Database Syst Rev. 2018;10:CD012414. doi:10.1002/14651858.CD012414.pub2

18. Sari Motlagh R, Abufaraj M, Yang L, et al. "Penile rehabilitation strategy after nerve-sparing radical prostatectomy: a systematic review and network meta-analysis of randomized trials." J Urol. 2021;205(4):1018–1030. doi:10.1097/JU.0000000000001584

19. Montorsi F, Brock G, Stolzenburg JU, et al. "Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a randomised placebo-controlled study (REACTT)." Eur Urol. 2014;65(3):587–596. doi:10.1016/j.eururo.2013.09.051

20. Jo JK, Jeong SJ, Oh JJ, et al. "Effect of starting penile rehabilitation with sildenafil immediately after robot-assisted laparoscopic radical prostatectomy on erectile function recovery: a prospective randomized trial." J Urol. 2018;199(6):1600–1606. doi:10.1016/j.juro.2017.12.060

21. Nauta MD, Falagario UG, Ricapito A, et al. "Sexual function recovery following open and robotic radical prostatectomy: results of an academic penile rehabilitation program." Asian J Androl. 2025. doi:10.4103/aja202525

22. Basal S, Wambi C, Acikel C, Gupta M, Badani K. "Optimal strategy for penile rehabilitation after robot-assisted radical prostatectomy based on preoperative erectile function." BJU Int. 2013;111(4):658–665. doi:10.1111/j.1464-410X.2012.11487.x

23. Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. "Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism." J Sex Med. 2006;3(6):1077–1084. doi:10.1111/j.1743-6109.2006.00333.x

24. Pereira DA, Calmasini FB, Costa FF, Burnett AL, Silva FH. "Nitric oxide resistance in priapism associated with sickle cell disease: mechanisms, therapeutic challenges, and future directions." J Pharmacol Exp Ther. 2024;390(2):203–212. doi:10.1124/jpet.123.001962

25. Bivalacqua TJ, Allen BK, Brock GB, et al. "The diagnosis and management of recurrent ischemic priapism, priapism in sickle cell patients, and non-ischemic priapism: an AUA/SMSNA guideline." J Urol. 2022;208(1):43–52. doi:10.1097/JU.0000000000002767

26. Hou LT, Burnett AL. "Regimented phosphodiesterase type 5 inhibitor use reduces emergency department visits for recurrent ischemic priapism." J Urol. 2021;205(2):545–553. doi:10.1097/JU.0000000000001365

27. Ilg MM, Mateus M, Stebbeds WJ, et al. "Antifibrotic synergy between phosphodiesterase type 5 inhibitors and selective oestrogen receptor modulators in Peyronie's disease models." Eur Urol. 2019;75(2):329–340. doi:10.1016/j.eururo.2018.10.014

28. Cosentino M, Di Nauta M, Boeri L, et al. "Conservative treatment of Peyronie's disease: a guide." World J Urol. 2024;42(1):317. doi:10.1007/s00345-024-04975-6

29. Spirito L, Manfredi C, La Rocca R, et al. "Daily low-dose tadalafil may reduce the penile curvature progression rate in patients with acute Peyronie's disease: a retrospective comparative analysis." Int J Impot Res. 2024;36(2):129–134. doi:10.1038/s41443-022-00651-8

30. Chung E, Deyoung L, Brock GB. "The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes." J Sex Med. 2011;8(5):1472–1477. doi:10.1111/j.1743-6109.2011.02217.x

31. Alzubaidi RT, Abdelkareem M, Al-Zoubi RM, et al. "Outcomes and management of Peyronie's disease with combined treatment of collagenase clostridium histolyticum, vacuum erection device, and tadalafil." Asian J Androl. 2025. doi:10.4103/aja202514

32. Rosenberg JE, Ergun O, Hwang EC, et al. "Non-surgical therapies for Peyronie's disease." Cochrane Database Syst Rev. 2023;7:CD012206. doi:10.1002/14651858.CD012206.pub2

33. Chen J, Keren-Paz G, Bar-Yosef Y, Matzkin H. "The role of phosphodiesterase type 5 inhibitors in the management of premature ejaculation: a critical analysis of basic science and clinical data." Eur Urol. 2007;52(5):1331–1339. doi:10.1016/j.eururo.2007.08.005

34. Sun Y, Yang L, Bao Y, et al. "Efficacy of PDE5Is and SSRIs in men with premature ejaculation: a new systematic review and five meta-analyses." World J Urol. 2017;35(12):1817–1831. doi:10.1007/s00345-017-2086-5

35. Jin K, Deng L, Qiu S, et al. "Comparative efficacy and safety of phosphodiesterase-5 inhibitors with selective serotonin reuptake inhibitors in men with premature ejaculation: a systematic review and Bayesian network meta-analysis." Medicine. 2018;97(49):e13342. doi:10.1097/MD.0000000000013342

36. Mitsogiannis I, Dellis A, Papatsoris A, Moussa M. "An up-to-date overview of the pharmacotherapeutic options for premature ejaculation." Expert Opin Pharmacother. 2022;23(9):1043–1050. doi:10.1080/14656566.2022.2035361

37. Sun F, Liu H, Wu G, et al. "Pooled analysis of tadalafil and tamsulosin for ureteral calculi." Front Pharmacol. 2024;15:1351312. doi:10.3389/fphar.2024.1351312

38. Sharma G, Kaundal P, Pareek T, et al. "Comparison of efficacy of various drugs used for medical expulsive therapy for distal ureter stones: a systematic review and network meta-analysis." Int J Clin Pract. 2021;75(9):e14214. doi:10.1111/ijcp.14214

39. Liu H, Wang S, Zhu W, et al. "Comparative efficacy of 22 drug interventions as medical expulsive therapy for ureteral stones: a systematic review and network meta-analysis." Urolithiasis. 2020;48(5):447–457. doi:10.1007/s00240-019-01159-5

40. American College of Obstetricians and Gynecologists. "Female sexual dysfunction: ACOG Practice Bulletin, Number 213." Obstet Gynecol. 2019;134(1):e1–e18. doi:10.1097/AOG.0000000000003324

41. Davis SR. "Sexual dysfunction in women." N Engl J Med. 2024;391(8):736–745. doi:10.1056/NEJMcp2313307

42. Gao L, Yang L, Qian S, et al. "Systematic review and meta-analysis of phosphodiesterase type 5 inhibitors for the treatment of female sexual dysfunction." Int J Gynaecol Obstet. 2016;133(2):139–145. doi:10.1016/j.ijgo.2015.08.015

43. Georgiadis G, Zisis IE, Docea AO, et al. "Current concepts on the reno-protective effects of phosphodiesterase 5 inhibitors in acute kidney injury: systematic search and review." J Clin Med. 2020;9(5):E1284. doi:10.3390/jcm9051284

44. Lledó-García E, Subirá-Ríos D, Rodríguez-Martínez D, et al. "Sildenafil as a protecting drug for warm ischemic kidney transplants: experimental results." J Urol. 2009;182(3):1222–1225. doi:10.1016/j.juro.2009.05.006

45. Perri A, Izzo G, Lofaro D, et al. "Erectile dysfunction after kidney transplantation." J Clin Med. 2020;9(6):E1991. doi:10.3390/jcm9061991

46. Lasaponara F, Sedigh O, Pasquale G, et al. "Phosphodiesterase type 5 inhibitor treatment for erectile dysfunction in patients with end-stage renal disease receiving dialysis or after renal transplantation." J Sex Med. 2013;10(11):2798–2814. doi:10.1111/jsm.12038

47. Trolle Lagerros Y, Grotta A, Freyland S, Grannas D, Andersson DP. "Risk of death in patients with coronary artery disease taking nitrates and phosphodiesterase-5 inhibitors." J Am Coll Cardiol. 2024;83(3):417–426. doi:10.1016/j.jacc.2023.10.041

48. Virani SS, Newby LK, Arnold SV, et al. "2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease." J Am Coll Cardiol. 2023;82(9):833–955. doi:10.1016/j.jacc.2023.04.003

49. Hentzen C, Musco S, Amarenco G, Del Popolo G, Panicker JN. "Approach and management to patients with neurological disorders reporting sexual dysfunction." Lancet Neurol. 2022;21(6):551–562. doi:10.1016/S1474-4422(22)00036-9